Norstictic acid is a lichen metabolite that has been found in R. farinacea and has antimicrobial and anticancer activities. It is active against A. hydrophilia, B. subtilis, L. monocytogenes, P. vulgaris, S. faecalis, C. albicans, and C. glabrata (MICs = 0.1-6.7 mM). Norstictic acid (1-100 μM) inhibits proliferation, migration, and invasion of MDA-MB-231 cells. In vivo, norstictic acid (15 mg/kg, i.p.) reduces tumor growth in an MDA-MB-231/GFP mouse xenograft model.
Norstictic acid significantlysuppressed the proliferation,migration and invasion. It alsosignificantly suppressedMDA-MB-231/GFP tumour growthof a breast cancer xenograft modelin athymic nude mice
Ebrahimet al. (2016)
Norstictic acid (NA) is a depsidone-derived metabolite common in several lichenspecies of the genera Usnea, Ramalina and Parmelia. Various biological activitieshave been reported for NA including antioxidant, antimicrobial and cytotoxic innature (White et al. 2014). Recently, Ebrahim et al. (2016) reported that administrationof NA to MDA-MB-231 cells significantly suppressed the proliferation,migration and invasion. Also, it showed minimal toxicity to non-tumorigenicMCF-10A mammary epithelial cells. They also performed molecular modelling,Z′-LYTE biochemical kinase assay and Western blot analysis, to identify c-Met asa potential macromolecular target. Further, NA treatment significantly suppressedMDA-MB-231/GFP tumour growth of a BC xenograft model in athymic nudemice. At this juncture, they concluded that lichen-derived natural products arepromising resources to discover novel c-Met inhibitors useful to control TNBC(Ebrahim et al. 2016).
